Prognostic significance of combined α-fetoprotein and CA19-9 for hepatocellular carcinoma after hepatectomy

Table 1 Clinicopathological characteristics of patients with hepatocellular carcinoma treated with hepatectomy and enrolled in the study

Variable	Patients (n = 711)		P	Patients (n = 711)		P
Variable	AFP ≤ 400 ng/mL (n = 381)	AFP > 400 ng/mL (n = 330)	P	CA19-9 ≤ 37 U/mL (n = 552)	CA19-9 > 37 U/mL (n = 159)	P
Sex			0.003			0.485
Male	339	268		474	133
Female	42	62		78	26
Age			0.008			0.781
≤60 years	300	285		453	132
>60 years	81	45		99	27
Tumor size
<5 cm	141	82	<0.001	179	44	0.255
≥5 cm	240	248		373	115
Number of tumors
<2	271	225	0.394	389	107	0.442
≥2	110	105		163	52
Tumor capsule			0.006			0.114
Complete	314	244		426	132
Incomplete	67	86		126	27
MVI			<0.001			0.469
Negative	189	115		240	64
Positive	192	215		312	95
BCLC stage			<0.001			0.058
A–B	289	189		381	97
C	92	141		171	62
Edmonson grade			<0.001			0.502
I–II	340	258		467	131
III–IV	41	72		85	28
HBsAg			0.141			<0.001
Negative	57	37		89	5
Positive	324	293		463	154
Liver cirrhosis			0.789			0.017
No	226	199		343	82
Yes	155	131		209	77
Child–Pugh score			0.082			0.142
A	369	326		542	153
B	12	4		10	6
Serum albumin			0.752			<0.001
<35 g/L	48	39		54	33
≥35 g/L	333	291		498	126
ALT			0.423			<0.001
≤40 U/L	236	214		383	67
>40 U/L	145	116		169	92
AST			0.024			<0.001
≤40 U/L	225	167		336	56
>40 U/L	156	163		216	103
TBil			0.385			0.008
≤17.1 μmol/mL	297	266		449	114
>17.1 μmol/mL	84	64		103	45

MVI microvascular invasion, BCLC Barcelona Clinic Liver Cancer Staging System, HBsAg hepatitis B surface antigen, ALT alanine aminotransferase, AST aspartate aminotransferase, TBil total bilirubin

ISSN: 1477-7819